Treatments reboxetine

Rare adverse event of severe neutropenia (3 of 2,796 patients) uncertain causal relationship to mirtazapine treatment Reboxetine... 

Scates, A. C. Doraiswamy, P. M. (2000). Reboxetine a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother., 34, 1302-12. 

Shen, Y. F., Li, H. F., Ma, C. et al. (2005). Comparison of reboxetine with fluoxetine in treatment of depressions randomized double-blind multicenter study. Chinese Journal of New Drugs and Clinical Remedies, 24(8), 619-23. 

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999 60 400-406. 

Reboxetine was first introduced to the European market in 1997 for the treatment of depression it is not yet available in the United States. Reboxetine represents a novel antidepressant class, the selective noradrenaline reuptake inhibitors (NRIs). 

In a 1-year, double-blind, placebo-controlled, long-term treatment study of 358 depressed patients, 22% of reboxetine-maintained patients relapsed versus 55% of those switched to placebo (276). 

Newer antidepressants. Although the SSRIs are the only antidepressants formally approved for the treatment of panic disorder, recent evidence suggests that several other antidepressants are promising treatments for panic disorder as well. These include nefazodone, venlafaxine XR, mirtazapine, and reboxetine. Bupropion, however, does not seem to have apparent antipanic actions. Since the documentation of efficacy of these newer antidepressants in panic disorder is still emerging, they tend to be used as second-line therapy after SSRIs foil to improve panic or in patients who cannot tolerate them. 

Novel antidepressants Given the importance of SSRIs in the treatment of panic disorder, other, newer antidepressants are developing an efficacy portfolio for panic disorder (and other anxiety disorders) as well. Thus, venlafaxine XR, nefazodone, and mirtazapine hold promise for the treatment of panic disorder. One early study also suggests that the new antidepressant reboxetine may be effective in panic disorder. 

The noradrenaline re-uptake inhibitor, reboxetine, does not cause weight gain during routine clinical use and indeed has been advocated as an adjunctive treatment in the management of olanzapine-induced weight gain. 

Lemke MR (2000) Reboxetine treatment of depression in Parkinson s disease. J. Clin. Psychiatry 61 872. 

In everyday interactions with their flatmates, the effects of 2 weeks treatment with reboxetine on social behaviours were different from those found in the stranger dyadic interaction. It was found that participants on reboxetine were rated to be less submissive on the IMI and as more passive participant on the 2DSIS by their flatmates (Tse and Bond, 2003). They were generally viewed more positively when on reboxetine and the treatment seemed to result in an enhancement of an already existing friendship. Thus, reboxetine seemed to help both the development and consolidation of social bonds via changes in social behaviours. 

Volunteers treated with reboxetine might be more co-operative and submissive to strangers which might help them to get on with people who are not known to them.. Social behaviour after reboxetine treatment could therefore be constructive to friendship development. The failure of 2 weeks reboxetine treatment to increase co-operative social behaviour on the Mixed-Motive game might lie in the fact that the difference between the points which the subjects awarded to themselves and to the confederate was very small. In the repeated dose reboxetine study, the subjects awarded the confederate more after both placebo and reboxetine. The subjects in this study therefore appear to be very co-operative, irrespective of treatment. 

Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003 18 151-6. 

It appears that, like SSRIs, reboxetine can cause sodium depletion in elderly people. However, in this case the contributions of concomitant general medical illness and its treatment were uncertain. 

Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002 12(2) 119-22. 

Gould GG, Pardon MC, Moiilak DA, Frazer A (2003) Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology 28 1633-1641... 

Fieishaker JC. Ciinicai pharmacokinetics of reboxetine, a seiective norepinephrine reuptake inhibitor for the treatment of patients with depression. Ciin Pharmacokinet 2000 39(6) 413-27. 

---